Day: April 29, 2020

The board of Skandinaviska Enskilda Banken AB has decided that the annual general meeting will be held on 29 June 2020. An invitation to the AGM with additional information will be published no later than four weeks before the AGM, in accordance with existing legislation.For further information, please contactChristoffer Geijer, Head of Investor Relations,  +46 70 762 10 06Frank Hojem, Head of Corporate Communication, +46 70 763 99 47 

Styrelsen i Skandinaviska Enskilda Banken AB har beslutat att årsstämman ska hållas den 29 juni 2020. Kallelse till stämman med ytterligare information kommer att utfärdas senast fyra veckor före årsstämman i överensstämmelse med gällande regelverk.För ytterligare information, kontaktaChristoffer Geijer, chef Investor Relations, 070-762 10 06Frank Hojem, chef Corporate Communication, 070-763 9947 

2020 First quarterPress release – Paris, April 29th, 2020Sales performance in line with expectationsQ1 2020 sales down -16.7% as reported; -20.4% on an organic1 basisFollowing good start to the year, Q1 sales impacted by Covid-19 in all regions from end of JanuaryChina traffic and sales gradually improving since March, showing early signs of recoveryClosure of 6 DOS2 in Q1 20, driven by a slowdown of international store openings and the French network optimization planExecution of action plans to mitigate the impact of crisis and protect cash positionGood performance in e-commerce driven by China; teams mobilized to foster digital salesCommenting on the report, Daniel Lalonde, SMCP’s CEO, stated: “Following a good start to the year, all regions have progressively been impacted by the lockdown measures due to the Covid-19 epidemic....

1er trimestre 2020Communiqué – Paris, le 29 avril 2020Chiffre d’affaires en ligne avec les prévisionsChiffre d’affaires en baisse de -16,7% en données publiées, soit un recul de -20,4% en organique1Après un bon début d’année, le chiffre d’affaires du T1 a été pénalisé par le Covid-19 dans l’ensemble des régions à partir de la fin du mois de janvierEn Chine Continentale, le trafic et les ventes s’améliorent progressivement depuis le mois de mars, illustrant les premiers signes d’une repriseFermeture de 6 points de vente2 (DOS) au T1 2020, liée au ralentissement des ouvertures à l’international et au plan d’optimisation du réseau de magasins en FranceMise en œuvre du plan d’actions pour atténuer les effets de la crise et préserver la trésorerieBonne performance du e-commerce portée par la Chine ; des équipes mobilisées pour favoriser les...

Interim report January – March 2020 January – March 2020Net sales increased by 47 percent to SEK 1,624.2 million (1,108.8). Organic growth in local currency was 32 percent.Gross profit increased by 54 percent to SEK 446.7 million (289.5). Organic growth in local currency was 36 percent.Adjusted EBITDA1 increased by 64 percent to SEK 184.3 million (112.2).Adjusted EBIT2 amounted to SEK 168.8 million (102.3).Profit after tax for the quarter amounted to SEK 96.4 million (57.8).Diluted earnings per share amounted to SEK 1.74 (1.08).”It is comforting to report strong financial performance in these times of unprecedented uncertainty” – Oscar Werner, CEOSignificant events during the quarterOn 19 March, Sinch entered into a definitive agreement to acquire Chatlayer BV for an enterprise value of EUR 6.9 million on debt-free basis. The acquisition...

Delårsrapport januari – mars 2020Januari – mars 2020Nettoomsättningen ökade med 47 procent till 1 624,2 MSEK (1 108,8). Den organiska tillväxten i lokal valuta var 32 procent.Bruttoresultatet ökade med 54 procent till 446,7 MSEK (289,5). Den organiska tillväxten i lokal valuta var 36 procent.Justerad EBITDA1 ökade med 64 procent till 184,3 MSEK (112,2).Justerad EBIT2 uppgick till 168,8 MSEK (102,3).Kvartalets resultat efter skatt uppgick till 96,4 MSEK (57,8).Resultat per aktie efter utspädning uppgick till 1,74 SEK (1,08).”Det är betryggande att kunna rapportera starka resultat under dessa osäkra omständigheter” – Oscar Werner, VDViktiga händelser under kvartaletDen 19 mars ingick Sinch ett bindande avtal att förvärva det belgiska bolaget Chatlayer BV för en total köpeskilling om 6,9 MEUR på skuldfri basis. Förvärvet finansieras med...

Basel, Switzerland, April 29, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Ms. Savitha Ram Moorthi will be appointed Head of Global Quality Management and a member of the Extended Management Committee of Basilea as of June 1, 2020. Ms. Ram Moorthi joined Basilea from Novo Nordisk Health Care, Zurich, Switzerland, on February 1, 2020, as Head of Quality Compliance Systems & Safety. She holds a Master’s Degree in Clinical Pharmacology from the University of Aberdeen, United Kingdom, and a Master’s in Pharmacy from Nagpur University, India. At Novo Nordisk, Ms. Ram Moorthi served as Director Clinical Quality and Pharmacovigilance responsible for the oversight of Quality Management Reviews, clinical quality and pharmacovigilance for International Operations. Prior to this, she worked as Director Clinical Operations...

Basel, 29. April 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass Frau Savitha Ram Moorthi zum 1. Juni 2020 zum Head of Global Quality Management und Mitglied der erweiterten Geschäftsleitung der Basilea ernannt wird. Frau Ram Moorthi kam als Head of Quality Compliance Systems & Safety am 1. Februar 2020 von Novo Nordisk Health Care, Zürich, zu Basilea. Sie verfügt über einen Master-Abschluss in klinischer Pharmakologie der Universität von Aberdeen, Grossbritannien, und einen Master-Abschluss in Pharmazie der Universität von Nagpur, Indien. Bei Novo Nordisk war Frau Ram Moorthi als Director Clinical Quality and Pharmacovigilance für die Leitung von Qualitätsmanagement-Reviews, klinische Qualität und Arzneimittelsicherheit (Pharmakovigilanz) für das internationale Geschäft verantwortlich. Davor war sie Director Clinical...

Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) disease spectrum There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US1 Cosentyx is also approved for the treatment of moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)2-4 This approval underlines Cosentyx leadership in rheumatology and immuno-dermatology, with plans to expand to 10 indications over the next 10 years Basel, April 29, 2020 — Novartis, a leader in rheumatology and immuno-dermatology,  today announced the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adult patients with active non-radiographic axial...

PRESS RELEASEFIRST-QUARTER 2020 BUSINESS REVIEWParis — April 29, 2020Key financials(1)Operating performanceRevenuesKlépierre’s total revenues for the three-month period ended March 31, 2020 amounted to €316.8 million, a 4.2% decrease compared to the same period last year, mainly attributable to the impact of disposals carried out in 2019.Gross rental income generated by shopping centers amounted to €291.9 million over the first quarter of 2020 on a total share basis, compared to €304.9 million for the same period last year. The €13.0-million (4.3%) decrease mainly reflects the disposal of assets in Hungary, Portugal and the Netherlands in 2019 as well as a negative foreign exchange effect from Scandinavian currencies.As of March 31, 2020, like-for-like basis(2) shopping centers net rental income was broadly stable compared to the same...